Pharma Capital
Market: NASDAQ
52-week High/Low:
Sector: Health Care, Equipment & Services
Market Cap: 0.00M

NephroGenex is an innovator in the development of drugs to treat kidney disease, with a first indication in diabetic nephropathy. We have been pioneering the development of PYRIDORIN® (pyridoxamine dihydrochloride), a late stage compound to treat diabetic patients with this slow-developing but potentially deadly disease. Pyridorin has the potential to slow or stabilize the progression to end-stage renal disease by inhibiting the formation of advanced glycation end products that have been implicated in the development of diabetic nephropathy.


Interactive graph

col 3
col 4
col 5
col 6

NephroGenex Timeline

View All

Market Reports Including NRX


© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.